These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 9768827

  • 1. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
    Sparano JA.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
    [Abstract] [Full Text] [Related]

  • 2. Strategies for reduction of anthracycline cardiac toxicity.
    Speyer J, Wasserheit C.
    Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
    [Abstract] [Full Text] [Related]

  • 3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L, Bramwell V, Moran LA.
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [Abstract] [Full Text] [Related]

  • 4. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
    Gershanovich ML, Moiceenko VM, Orlova RV.
    Vopr Onkol; 1993 Apr; 39(1-3):26-32. PubMed ID: 8073671
    [Abstract] [Full Text] [Related]

  • 5. Doxorubicin plus paclitaxel in advanced breast cancer.
    Dombernowsky P, Boesgaard M, Andersen E, Jensen BV.
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-15-S17-8. PubMed ID: 9374086
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
    Sparano JA, Speyer J, Gradishar WJ, Liebes L, Sridhara R, Mendoza S, Fry D, Egorin MJ.
    J Clin Oncol; 1999 Mar; 17(3):880-6. PubMed ID: 10071279
    [Abstract] [Full Text] [Related]

  • 7. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M, Vici P.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [Abstract] [Full Text] [Related]

  • 8. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA.
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [Abstract] [Full Text] [Related]

  • 9. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
    Sparano JA.
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):14-9. PubMed ID: 10426454
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN.
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
    Imondi AR, Della Torre P, Mazué G, Sullivan TM, Robbins TL, Hagerman LM, Podestà A, Pinciroli G.
    Cancer Res; 1996 Sep 15; 56(18):4200-4. PubMed ID: 8797592
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE.
    Semin Oncol; 2006 Jun 15; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
    Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, Buzdar AU.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 17):S17-65-S17-68. PubMed ID: 9374097
    [Abstract] [Full Text] [Related]

  • 18. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH.
    Cancer Chemother Pharmacol; 2004 Sep 15; 54(3):241-8. PubMed ID: 15173955
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.